- Home
- SJT vs CHRS Comparison
SJT vs CHRS Comparison
Compare SJT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- CHRS
- Stock Information
- Founded
- SJT 1980
- CHRS 2010
- Country
- SJT United States
- CHRS United States
- Employees
- SJT N/A
- CHRS N/A
- Industry
- SJT Oil & Gas Production
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJT Energy
- CHRS Health Care
- Exchange
- SJT Nasdaq
- CHRS Nasdaq
- Market Cap
- SJT 181.8M
- CHRS 191.3M
- IPO Year
- SJT N/A
- CHRS 2014
- Fundamental
- Price
- SJT $4.51
- CHRS $1.44
- Analyst Decision
- SJT
- CHRS Strong Buy
- Analyst Count
- SJT 0
- CHRS 4
- Target Price
- SJT N/A
- CHRS $5.38
- AVG Volume (30 Days)
- SJT 293.9K
- CHRS 2.2M
- Earning Date
- SJT 11-14-2024
- CHRS 11-06-2024
- Dividend Yield
- SJT 2.52%
- CHRS N/A
- EPS Growth
- SJT N/A
- CHRS N/A
- EPS
- SJT 0.19
- CHRS N/A
- Revenue
- SJT $11,031,594.00
- CHRS $304,340,000.00
- Revenue This Year
- SJT N/A
- CHRS $2.47
- Revenue Next Year
- SJT N/A
- CHRS N/A
- P/E Ratio
- SJT $23.75
- CHRS N/A
- Revenue Growth
- SJT N/A
- CHRS 44.19
- 52 Week Low
- SJT $3.21
- CHRS $0.66
- 52 Week High
- SJT $5.81
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- SJT 65.45
- CHRS 48.85
- Support Level
- SJT $4.07
- CHRS $1.44
- Resistance Level
- SJT $4.28
- CHRS $1.77
- Average True Range (ATR)
- SJT 0.20
- CHRS 0.13
- MACD
- SJT 0.07
- CHRS -0.03
- Stochastic Oscillator
- SJT 94.44
- CHRS 21.43
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.